


| | | | |
|---|------|--------------------------|----------------------------------|
| Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i> | | Complete if Known | |
| | | Application Number | New Application |
| | | Filing Date | herewith |
| | | First Named Inventor | Repke, David Bruce et al. |
| | | Art Unit | to be assigned |
| | | Examiner Name | to be assigned |
| Sheet 1 | of 1 | Attorney Docket Number | R0152B-REG |

| U.S. PATENT DOCUMENTS | | | | | |
|-----------------------|-----------------------|--|--------------------------------|---|---|
| Examiner Initials * | Cite No. ¹ | Document Number | Publication Date MM-DD-YYYY | Name of Patentee or Applicant of Cited Document | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear |
| | | Number - Kind Code ² (if known) | | | |
| BML | A1 | US-3,733,321 | 05-15-1973 | John Krapcho | |
| | A2 | US-4,078,062 | 03-07-1978 | John Krapcho | |
| BML | A3 | US-6,410,536 B1 | 06-25-2002 | Danette Andrea Dudley et al. | |

| FOREIGN PATENT DOCUMENTS | | | | | | |
|--------------------------|-----------------------|---|--------------------------------|---|---|----------------|
| Examiner Initials * | Cite No. ¹ | Foreign Patent Document | Publication Date MM-DD-YYYY | Name of Patentee or Applicant of Cited Document | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear | T ⁶ |
| | | Country Code ³ - Number ⁴ - Kind Code ⁵ (if known) | | | | |
| BML | B1 | WO 99/50254 A1 | 10-07-1999 | Wamer-Lambert Co. (USA) | | |
| | B2 | WO 99/50257 A1 | 10-07-1999 | dto. | | |
| | B3 | WO 99/50263 A1 | 10-07-1999 | dto. | | |
| | B4 | WO 01/12187 A2 | 02-22-2001 | Astrazeneca AB (SE) | | |
| | B5 | WO 01/57003 A1 | 08-09-2001 | Cor Therapeutics (US) | | |
| | B6 | WO 01/57019 A1 | 08-09-2001 | dto. | | |
| BML | B7 | WO 01/74775 A1 | 10-11-2001 | Foulon, Loic et al. (FR) | with English Abstract | |

| OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS | | | |
|--|-----------------------|---|----------------|
| Examiner Initials * | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ² |
| | | | |

| | | | |
|--------------------|---|-----------------|---------|
| Examiner Signature |  | Date Considered | 9/19/04 |
|--------------------|---|-----------------|---------|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450. Doc. #123797v1